ALNY vs INTT · P/E 76, rev $1.29B vs P/E 444, rev $33.9M
Alnylam Pharmaceuticals Inc (ALNY) versus inTest Corporation (INTT) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
inTest Corporation (INTT) is a semiconductor equipment & materials company listed on AMEX.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported INTT revenue for 2026-03-31 was $33.9M. Net income was $789.0K. Revenue was down 58.2% from 2025-09-30 to 2026-03-31. INTT currently screens at market cap $223.3M and trailing P/E 444.3.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. INTT currently screens at market cap $223.3M and trailing P/E 444.3.
Not investment advice. Open the ALNY and INTT stock pages for the full models.
Not investment advice.